SIRION Biotech

Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development

Sirion Biotech to Attend ESGCT XXV Anniversary Congress

Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society for Gene Therapy...

Sirion Biotech to Attend ESGCT XXV Anniversary Congress

CAR-T Acknowledged by FDA Committee

Novartis has announced its CAR-T cell therapy CTL019 has been recommended by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee...

CAR-T Acknowledged by FDA Committee

Sirion Biotech Viral Vector Experience

Gene delivery by viral vectors has taken centre stage in the development of gene therapies and immuno-oncologies. It has revolutionised the precision that complex cell models can be...

Sirion Biotech Viral Vector Experience

Viral Vectors Engineered for Academic and Clinical Research

Off-the shelf virus vectors are naturally limited to answer only a basic set of questions. This can lead experimenters to compromise their...

Viral Vectors Engineered for Academic and Clinical Research

Using Viral Vectors to Reach Higher Transduction Levels

Known as transduction, the application of virus particles to deliver gene constructs to a cell is one of the best and most efficient ways to genetically modify mammalian or human...

Using Viral Vectors to Reach Higher Transduction Levels

Vaccunation and Immune Oncology Tool Ad19a/64 Acts as a Prime Reagent in a Two-Step Prime Boost Vaccination Approach

Sirion Biotech has announced that the Ad19a/64 vectors, considered by insiders as a promising vaccination and immune oncolgy tool, can act as a powerful prime reagent in a two-step prime...

Vaccunation and Immune Oncology Tool Ad19a/64 Acts as a Prime Reagent in a Two-Step Prime Boost Vaccination Approach